ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia

Esperion Therapeutics (ESPR) announced that it has come to an alignment with the FDA for initiating two phase III studies. The studies will evaluate bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). The phase III studies are expected to begin later in 2025.Esperion markets bempedoic acid as Nexletol and Nexlizet for treating elevated LDL-C (bad cholesterol) and cardiovascula ...